Last Update Time:
12-Mar-2025 16:00:00
ISIN:
INE406A01037
Sector:
Healthcare
Symbol:
AUROPHARMA
Aurobindo Pharma Limited
₹1,109.00
₹18.35
(1.68%)
▲
Prev. Close
₹1,090.65
Open
₹1,090.00
Close
₹1,107.90
Range
₹1,053.55 - ₹1,164.45
High
₹1,112.90
Low
₹1,080.25
Ind. Close
₹0.00
VWAP
₹1,096.64
The current stock price of Aurobindo Pharma Limited is ₹1,109.00, with a target price range between ₹1,053.55 and ₹1,164.45. The stock has experienced a price change of ₹18.35 (1.68%), reflecting recent market volatility.
Today's opening price was ₹1,090.00, while the previous close stood at ₹1,090.65.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Aurobindo Pharma Limited Price Chart
Aurobindo Pharma Limited Pre Open Market Overview: 12-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1090
- Previous Close Price: 1090.65
- Change: -0.65%
- Total Traded Volume: 923
- Total Buy Quantity: 7,259
- Total Sell Quantity: 3,496
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,085.35 | 1.00 | 0.00 |
| 1,086.50 | 400.00 | 0.00 |
| 1,087.00 | 1.00 | 0.00 |
| 1,087.10 | 2,000.00 | 0.00 |
| 1,087.15 | 300.00 | 0.00 |
| 1,090.00 | 0.00 | 26.00 |
| 1,090.65 | 0.00 | 15.00 |
| 1,090.80 | 0.00 | 10.00 |
| 1,091.15 | 0.00 | 1.00 |
| 1,091.45 | 0.00 | 7.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 7259
Total Sell Quantity: 3496
Shareholding Patterns of Aurobindo Pharma Limited
Key Trade Statistics of Aurobindo Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 8.95 |
| Traded Value (₹ Cr.) | 98.20 |
| Total Market Cap (₹ Cr.) | 64,410.90 |
| Free Float Market Cap (₹ Cr.) | 30,903.94 |
| Impact cost | 0.03 |
| Quantity Traded | 895,448.00 |
| Deliverable Quantity | 508,479.00 |
| % of Quantity to Traded | 56.78 |
| Security VaR | 11.47 |
| Index VaR | N/A |
| VaR Margin | 11.47 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 14.97 |
| Face Value | 1 |
Key Price Statistics of Aurobindo Pharma Limited
The 52-week high for Aurobindo Pharma Limited was ₹1,592.00, recorded on 13-Sep-2024. On the other hand, the 52-week low stands at ₹984.30, with the lowest value recorded on 15-Mar-2024.
The upper band for trading is ₹1,199.70, and the lower band is ₹981.60. The price band is No Band%.
The stock's daily volatility stands at 1.81, while the annualized volatility is 34.58. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (13-Sep-2024) | 1,592.00 |
| 52 Week Low (15-Mar-2024) | 984.30 |
| Upper Band | 1,199.70 |
| Lower Band | 981.60 |
| Price Band (%) | No Band |
| Daily Volatility | 1.81 |
| Annualised Volatility | 34.58 |
| Tick Size | 0.05 |
Key Securities Statistics of Aurobindo Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 19-Jul-2000 |
| Adjusted P/E | 17.76 |
| Symbol P/E | 18.1 |
| Index | NIFTY MIDCAP 50 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Aurobindo Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Aurobindo Pharma Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 12-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 11-Mar-2025 |
| General Updates | 05-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 04-Mar-2025 |
| Action(s) initiated or orders passed | 01-Mar-2025 |
| Acquisition | 28-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 20-Feb-2025 |
| Updates | 20-Feb-2025 |
Corporate Actions of Aurobindo Pharma Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Annual General Meeting | 26-Aug-2024 |
| 1 | Buy Back | 30-Jul-2024 |
| 1 | Interim Dividend - Rs 1.50 Per Share | 20-Feb-2024 |
| 1 | Interim Dividend - Rs 3 Per Share | 20-Nov-2023 |
| 1 | Annual General Meeting | 22-Aug-2023 |
| 1 | Interim Dividend - Rs 3 Per Share | 17-Feb-2023 |
| 1 | Annual General Meeting | 27-Jul-2022 |
| 1 | Interim Dividend - Rs 4.50 Per Share | 06-Jun-2022 |
| 1 | Interim Dividend - Rs 1.50 Per Share | 18-Feb-2022 |
| 1 | Interim Dividend - Rs 1.50 Per Share | 17-Nov-2021 |
| 1 | Interim Dividend - Rs 1.50 Per Share | 27-Aug-2021 |
| 1 | Annual General Meeting | 20-Aug-2021 |
| 1 | Interim Dividend - Rs 1.50 Per Share | 22-Feb-2021 |
| 1 | Interim Dividend - Rs 1.25 Per Share | 23-Nov-2020 |
| 1 | Annual General Meeting/Interim Dividend - Rs 1.25 Per Share | 21-Aug-2020 |
| 1 | Interim Dividend - Rs 1.75 Per Share | 17-Feb-2020 |
| 1 | Interim Dividend - Rs 1.25 Per Share | 21-Nov-2019 |
| 1 | Annual General Meeting | 21-Aug-2019 |
| 1 | Interim Dividend - Rs 1.25 Per Share | 15-Feb-2019 |
| 1 | Interim Dividend - Rs 1.25 Per Share | 20-Nov-2018 |
Board Meetings of Aurobindo Pharma Limited
Financial Results of Aurobindo Pharma Limited
Company Directory of Aurobindo Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| N/A | Head Office/ Corporate Office | Galaxy, Floor 22-24, Plot No. 1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmaktha Hyderabad | HYDERABAD |
| N/A | Registered Office | Plot no. 2, Maithrivihar, Behind Maithri Vanam, Ameerpet, | N/A |
| N/A | Transfer Agent | KFin Technologies Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally Mandal | HYDERABAD |
Insider Trading of Aurobindo Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 12668544753 | Pledge Revoke |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 17585935000 | Pledge |
| 7(2) | PAVANKUMAR PS | 1022000 | Sell |
| 7(2) | CHANDRASEKHAR REDDY KANDATI | 2094775 | Sell |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 10490190000 | Pledge Revoke |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 2400740000 | Pledge Revoke |
| 7(2) | ROOPAK SAWHNEY | 3923040 | Sell |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 13347740000 | Pledge |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 13347740000 | Pledge |
| 7(2) | K BHARATHI | 35598850 | Sell |
| 7(2) | K BHARATHI | 35598850 | Sell |
| 7(2) | GITA RAO | 1277900 | Sell |
| 7(2) | GITA RAO | 1277900 | Sell |
| 7(2) | S BALA SUBRAMANYAM REDDY | 2054000 | Sell |
| 7(2) | S BALA SUBRAMANYAM REDDY | 2054000 | Sell |
| 7(2) | ROOPAK SAWHNEY | 3923040 | Sell |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 279712500 | Pledge |
| 7(2) | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | 449920000 | Pledge Revoke |
| 7(2) | K R VIJAYAPAL REDDY | 1082600 | Sell |
| 7(2) | Akkiraju Venkata Satya Murali Mohan | 4310000 | Sell |
Annual Reports of Aurobindo Pharma Limited
Investor Complaints of Aurobindo Pharma Limited
Event Calendar of Aurobindo Pharma Limited
| Purpose | Details |
|---|---|
| Scheme of Arrangement | To consider a Scheme of Arrangement. |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2010 and recommendation of final dividend, if any, for the financial year ended March 31, 2010. In view of this, the Company will not be publishing the un-audited quarterly financial results of last quarter ending March 31, 2010. |
| Results/Dividend | The Company had informed the Exchange that a Meeting of the Board of the Company will be held on November 03, 2010 to consider inter-alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2010.The Company has now informed the Exchange that the Board at the Meeting to be held on November 03, 2010 will also consider the proposal for payment of Interim dividend for the year 2010-11. (Purpose Revised). |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2011 and recommendation of final dividend, if any, for the financial year ended March 31, 2011. |
| Board Meeting Postponed | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on February 10, 2012 to consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2011. The Company has now informed the Exchange that aforesaid Board Meeting has been postponed due to unavoidable circumstances. The meeting is now scheduled to be held on February 13, 2012. |
| Results/Dividend | The Company had informed the Exchange regarding a Board meeting to be held on May 29, 2012 inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2012. The Company has now informed the Exchange that at the said Board meeting the Board will also consider recommendation of Dividend, if any, for the year 2011-12.(Purpose Revised) |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on February 07, 2013 To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2012. The Company has now informed the Exchange that the Meeting of the Board will also consider the proposal of payment of Interim Dividend for the year 2012-13.(Purpose Revised) |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013.Further, the Board will also consider recommendation of Final Dividend, if any, for the year 2012-13. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2013. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30,2013. |
| Results/Dividend | The company had informed the Exchange that the meeting of the Board of Directors of the Company is scheduled to be held on November 07, 2013 to consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2013. The company has now informed the Exchange that, in the aforesaid meeting, the Board will also consider the proposal of payment of Interim Dividend for the year 2013-14. (Purpose Revised). |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2013. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 30, 2014 Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2014. The Board will also consider recommendation of Final Dividend, if any, for the year 2013-14. The Company has now informed the Exchange that the Board will consider the proposal of Second Interim Dividend and Final Dividend, if any, for the year 2013-14.(Purpose Revised) |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2014. Further at the said Board meeting the Board will also consider recommendation of Final Dividend, if any, for the year 2013-14. |
| Results | to consider, inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2014. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2014. |
| Issue of Securities | to inter alia consider raising of funds through issue of securities. |
| Results/Dividend | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2014. Further, the Board will also consider 2nd interim Dividend, if any, for the financial year 2014-15. |
| Results/Dividend | Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2015. Further at the said Board meeting the Board will also consider payment of Dividend, if any, for the year 2014-15. |
| Results/Dividend | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held on August 12, 2015, to consider, inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2015.The Company has now informed the Exchange that the meeting of the Board of Directors of the Company schedule to be held on August 12, 2015, will also consider the proposal of payment of Interim Dividend for the year 2015-16. (Purpose Revised) |
| Results | To consider, inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2015. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30,2015. |
| Results/Dividend | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held November 6, 2015 to consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30,2015.The Company has now informed the Exchange that the meeting of the Board of Directors will also consider the proposal of payment of Second Interim Dividend for the year 2015-16 (Purpose Revised). |
| Results/Dividend | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held November 6, 2015 to consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2015 & will consider the proposal of payment of Second Interim Dividend for the year 2015-16.The Company has now informed the Exchange that the meeting of the Board of Directors will also discuss raising of funds through issue of securities (Purpose Revised). |
| Results | to consider, inter alia, the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2015. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on February 9, 2016, to consider, inter alia, the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2015. The Company has now informed the Exchange that the Board will also consider the proposal of payment of Third Interim Dividend for the year 2015-16. |
| Results/Dividend | To consider, inter alia, the Audited Financial Results of the Company for the year ended 31st March 2016. Further, the Board will also consider the proposal of payment of Dividend, if any, for the year 2015-16. |
| Results | To consider, inter alia, the Unaudited Financial Results of the Company for the first quarter ended June 30, 2016 of the Financial Year 2016-17. |
| Results/Dividend | to consider the Un-audited Financial Results of the Company for the second quarter and half year ended 30th September, 2016 of the FY 2016-17. The Board will also consider the proposal of payment of Interim Dividend for the year 2016-17. |
| Results | to consider, inter alia, the Un-Audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2016. |
| Results/Dividend | to consider and approve, inter alia, the Audited Financial Results of the Company for the year ended March 31, 2017 and also to consider dividend, if any, for the financial year 2016-17. |
| Results | To consider and approve, inter alia, the Un-audited Financial Results of the Company for the first quarter ended June 30, 2017. |
| Results/Dividend | to consider and approve, inter alia, the Un-audited Financial results of the Company for the second quarter and half year ended September 30, 2017 and also to consider interim dividend, if any, for the financial year 2017-18. |
| Results | to consider and approve, inter alia, the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2017. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on February 07, 2018 to consider and approve, inter alia, the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2017. The company has now inform the exchange that at the aforesaid Board meeting , the Board will also consider the proposal of payment of Second Interim Dividend for the financial Year 2017-18. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results | We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Thursday, 9th August, 2018 to consider and approve, inter alia, the Un-audited Financial Results of the Company for the first quarter ended 30th June, 2018.Further to our letter dated 26th July, 2018 informing the closure of Trading Window of the Company from 30th July, 2018 until 48 hours from the date of declaration of the Un-audited Financial Results of the Company for the first quarter ended 30th June, 2018, we would like to inform you that the Trading Window will be closed up to 11th August, 2018 and shall be re-opened on 12th August, 2018. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2018 and Interim Dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2019 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2020 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2021 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2021 and dividend |
| Financial results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, August 11, 2022 to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2022.Further to our letter dated June 28, 2022 informing the closure of Trading Window of the Company from July 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022, we inform you that the Trading Window will remain closed up to August 13, 2022 and shall be re-opened on August 14, 2022. |
| Financial results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Saturday, November 12, 2022 to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022.Further to our letter dated September 28, 2022 informing the closure of Trading Window of the Company from October 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022, we inform you that the Trading Window will remain closed up to November 14, 2022 and shall be re-opened on November 15, 2022. |
| Financial Results/Dividend | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, February 9, 2023 to consider and approve inter alia, the following:1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022 and2. Payment of Interim Dividend, if any, for the financial year 2022-23.Further to our letter dated December 29, 2022 informing about the closure of Trading Window of the Company from January 1, 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022, we inform you that the Trading Window will remain closed up to February 11, 2023 and shall be re-opened on February 12, 2023. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Aurobindo Pharma Limited
Voting Results of Aurobindo Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 29-AUG-2024 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2024, and reports of Directors and Auditors thereon. |
| 29-AUG-2024 | AGM | To approve payment of commission to independent directors |
| 29-AUG-2024 | AGM | To ratify the remuneration payable to the Cost Auditors for the financial year 2024-25 |
| 29-AUG-2024 | AGM | To approve the continuation of Mr. P. V. Ramprasad Reddy (DIN: 01284132) as a Non-Executive Director of the Company |
| 29-AUG-2024 | AGM | To re-appoint Mr. M. Madan Mohan Reddy (DIN: 01284266) as Whole-time Director |
| 29-AUG-2024 | AGM | To re-appoint Mr. K. Nithyananda Reddy (DIN: 01284195) as Vice Chairman & Managing Director |
| 29-AUG-2024 | AGM | To appoint a Director in place of Mr. M. Madan Mohan Reddy (DIN: 01284266) who retires by rotation at this Annual General Meeting and being eligible, seeks re-appointment. |
| 29-AUG-2024 | AGM | To appoint a Director in place of Mr. K. Nithyananda Reddy (DIN: 01284195) who retires by rotation at this Annual General Meeting and being eligible, seeks re-appointment. |
| 29-AUG-2024 | AGM | To confirm the interim dividend of Rs.3.00 and second interim dividend of Rs.1.50 in aggregate Rs.4.50 per equity share of Re.1 each, as dividend paid for the financial year 2023-24. |
| 29-AUG-2024 | AGM | To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2024, and report of Auditors thereon. |
| 07-MAY-2024 | Postal Ballot | Appointment of Mr. Mangalam Ramasubramanian Kumar (DIN 03628755), as an Independent Director of the Company not liable to retire by rotation, for a period of 3 (Three) consecutive years commencing from April 1, 2024 to March 31, 2027. |
| 26-MAR-2024 | Postal Ballot | Appointment of Dr. (Mrs.) Deepali Pant Joshi (DIN: 07139051) as an Independent Director of the Company not liable to retire by rotation, for a period of 2 (Two) consecutive years commencing from February 10, 2024, to February 9, 2026. |
| 26-DEC-2023 | Postal Ballot | Appointment of Dr. Satakarni Makkapati (DIN: 09377266) as a Non-executive and Non-independent Director of the Company. |
| 26-DEC-2023 | Postal Ballot | Revision of remuneration of Mr. M. Madan Mohan Reddy (DIN: 01284266), Whole-time Director of the Company |
| 26-DEC-2023 | Postal Ballot | Revision of remuneration of Mr. K. Nithyananda Reddy (DIN: 01284195), Vice Chairman & Managing Director of the Company |
| 25-AUG-2023 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2023 and reports of Directors and Auditors thereon. |
| 25-AUG-2023 | AGM | To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2023-24 pursuant to Section 148 and all other applicable provisions of the Companies Act, 2013. |
| 25-AUG-2023 | AGM | To appoint a Director in place of Mr. P. Sarath Chandra Reddy (DIN: 01628013) who retires by rotation at this Annual General Meeting and being eligible, seeks reappointment. |
| 25-AUG-2023 | AGM | To confirm the interim dividend of Rs.3.00 per equity share of Re.1 each, as dividend paid for the financial year 2022-23. |
| 25-AUG-2023 | AGM | To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2023 and report of Auditors thereon. |
FAQs on Aurobindo Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.